维、汉前列腺癌患者内分泌治疗敏感时间相关因素分析

发布时间：2018-04-02 11:36

本文选题：前列腺癌　切入点：内分泌治疗　出处：《新疆医科大学》2016年硕士论文

【摘要】：目的:探讨新疆地区维吾尔族与汉族前列腺癌患者内分泌治疗敏感时间及其影响内分泌治疗敏感时间的临床因素,为新疆地区前列腺癌患者的个体化治疗提供依据。方法:将内分泌治疗至进展为去势抵抗性前列腺癌(CRPC)的时间定义为内分泌治疗敏感时间,回顾性分析111例单纯内分泌治疗的维吾尔族和汉族前列腺癌患者的临床资料,建立Cox回归模型,分析各临床因素和内分泌治疗敏感时间的相关关系。结果:单因素分析显示,民族(P=0.508)、年龄(P=0.099)、治疗方式(P=0.399)与内分泌治疗敏感时间无相关性。而初始PSA、临床分期、Gleason评分、PSA最低值、骨转移情况与内分泌治疗敏感时间存在显著相关关系(P0.05)。多因素分析显示,仅临床分期(P=0.000)和最低PSA值(P=0.000)是前列腺癌患者内分泌治疗敏感时间的主要影响因素。临床分期越高,内分泌治疗后越早出现CRPC。内分泌治疗后PSA能降至0.2 ng/m L及以下的患者较晚发展为CRPC。结论:新疆地区维吾尔族与汉族前列腺癌患者内分泌治疗敏感时间无差异,而临床分期与PSA最低值是前列腺癌内分泌治疗敏感时间的独立危险因素。
[Abstract]:Objective: to explore the sensitive time of endocrine therapy in Uygur and Han cancer patients in Xinjiang and the clinical factors influencing the sensitive time of endocrine therapy. Methods: the time from endocrine therapy to castrated resistant prostate cancer (CRPC) was defined as the sensitive time of endocrine therapy. The clinical data of 111 patients with prostate cancer in Uygur and Han nationality were analyzed retrospectively. Cox regression model was established to analyze the relationship between the clinical factors and the sensitive time of endocrine therapy. There was no correlation between the sensitive time of endocrine therapy and PSAs, the Gleason score of clinical stage and the lowest value of PSA, bone metastasis and sensitive time of endocrine therapy. The multivariate analysis showed that, in addition, there was a significant correlation between P0. 05 and P0. 05% of the patients with bone metastases and the sensitive time of endocrine therapy. Multivariate analysis showed that PSAs, Gleason score and PSA were the lowest values in clinical stage, and there was a significant correlation between bone metastasis and sensitive time of endocrine therapy. Only clinical staging (P0. 000) and minimum PSA value (0. 000) were the main factors influencing the sensitive time of endocrine therapy in patients with prostate cancer. The higher the clinical stage was, the higher the clinical stage was. The earlier CRPC appeared after endocrine therapy, the later the patients whose PSA could decrease to 0.2 ng/m L or less after endocrine therapy developed to CRPC.Conclusion: there is no difference in sensitive time of endocrine therapy between Uygur and Han patients in Xinjiang. The clinical stage and PSA minimum were independent risk factors for the sensitive time of endocrine therapy of prostate cancer.
【学位授予单位】：新疆医科大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R737.25

【相似文献】